Altre lingue Eyenovia, Inc.

Azioni

EYEN

US30234E1047

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
0,6282 ^USD	-11,68%		+10,09%	-69,80%

25/04	Eyenovia fornisce un aggiornamento clinico e scientifico sui prodotti approvati dalla FDA Mydcombi e Clobetasolo Propionato Sospensione Oftalmica	CI
08/04	Eyenovia valuterà una potenziale vendita e altre alternative strategiche	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension	25/04
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension	25/04
Eyenovia to Weigh Potential Sale, Other Strategic Alternatives	08/04
Eyenovia Explores Wide Range of Strategic Alternatives	08/04
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities	08/04
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings	03/04
Eyenovia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	18/03
North American Morning Briefing : Investors -2-	18/03
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment, Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023	15/03
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals	13/03
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals	13/03
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th	11/03
Eyenovia Reports FDA Approval for Formosa's Post-Op Eye Inflammation, Pain Treatment	05/03
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery	05/03
US FDA approves Eyenovia's eye drug, Formosa Pharma says	05/03
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility	13/02
Eyenovia, Inc Announces FDA Approval of Redwood City as Commercial Manufacturing Facility	13/02
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada	16/01
Eyenovia, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Eyenovia, Inc.

Azioni

EYEN

US30234E1047

Altre lingue

Filtri